Since the introduction of insulin in the treatment of patients with diabetes, various investigations have been conducted to find a remedy which would exert an influence on diabetes similar to that of insulin, but which could be administered orally.
During the course of the last year, a synthetic compound named "synthalin" was developed by Frank1 in Minkowski's clinic2 in Breslau. The exact chemical composition of this substance is deca-methyl-diguanidine,
In their first communication, these authors report that they were able to reduce the blood sugar concentration in completely depancreatized dogs and rabbits by administering synthalin either subcutaneously or orally. In these animals the blood dextrose dropped from 314 mg. per hundred cubic centimeters of blood to 70, and from 426 to 90. The clinical symptoms of hypoglycemia, convulsions and general paralysis, from which the animals recovered on the administration of dextrose, accompanied this drop in the blood sugar.
RINGER AI, BILOON S, HARRIS MM, LANDY A. SYNTHALIN: ITS USE IN THE TREATMENT OF DIABETES. Arch Intern Med (Chic). 1928;41(4):453–471. doi:10.1001/archinte.1928.00130160003001
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: